Sionna Therapeutics (NASDAQ:SION) Upgraded to “Sector Perform” at Royal Bank Of Canada

Sionna Therapeutics (NASDAQ:SION) was upgraded by equities researchers at Royal Bank Of Canada from an “underperform” rating to a “sector perform” rating in a report issued on Monday. The firm currently has a $5.00 target price on the stock. Royal Bank Of Canada’s target price points to a potential upside of 23.30% from the company’s current price.

Several other research firms also recently commented on SION. Raymond James Financial reiterated a “strong-buy” rating and issued a $59.00 price target on shares of Sionna Therapeutics in a research report on Thursday. Guggenheim upped their target price on shares of Sionna Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Friday. Wedbush reissued a “neutral” rating and set a $5.00 price target on shares of Sionna Therapeutics in a report on Monday. Stifel Nicolaus reaffirmed a “hold” rating and set a $7.00 price objective on shares of Sionna Therapeutics in a research note on Monday. Finally, JonesTrading increased their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Sionna Therapeutics presently has an average rating of “Hold” and a consensus price target of $42.22.

Sionna Therapeutics Price Performance

Shares of SION traded down $46.98 during midday trading on Monday, reaching $4.05. 23,315,454 shares of the stock were exchanged, compared to its average volume of 548,288. Sionna Therapeutics has a twelve month low of $4.01 and a twelve month high of $54.97. The company has a market capitalization of $183.33 million, a price-to-earnings ratio of -1.88 and a beta of 1.32. The business’s 50-day moving average price is $42.35 and its 200 day moving average price is $40.42.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). As a group, equities research analysts expect that Sionna Therapeutics will post -2.63 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Orbimed Advisors Llc sold 115,844 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the sale, the director owned 2,555,877 shares in the company, valued at $116,292,403.50. This trade represents a 4.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 115,844 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the sale, the director directly owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. This represents a 4.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 403,726 shares of company stock valued at $18,259,354 over the last three months. 5.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sionna Therapeutics

A number of large investors have recently made changes to their positions in SION. UBS Group AG increased its holdings in Sionna Therapeutics by 91.1% in the fourth quarter. UBS Group AG now owns 89,177 shares of the company’s stock valued at $3,669,000 after buying an additional 42,511 shares in the last quarter. Vanguard Group Inc. grew its holdings in Sionna Therapeutics by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares during the last quarter. Jennison Associates LLC increased its position in shares of Sionna Therapeutics by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after buying an additional 117,903 shares in the last quarter. Candriam S.C.A. acquired a new position in shares of Sionna Therapeutics during the 1st quarter worth $9,494,000. Finally, Eventide Asset Management LLC purchased a new stake in shares of Sionna Therapeutics in the 4th quarter worth about $26,290,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.